Adiponectin, Non-Esterified Fatty Acids and Antiphospholipid Antibodies in Type II Diabetes Mellitus
The importance of the association of antiphospholipid antibodies (aPL Abs) with the features of type II diabetes mellitus has not yet been elucidated. The aim of this work was to investigate the association of aPL Abs with adiponectin and non-esterified fatty acids (NEFA) in type II diabetes mellitus patients without micro and/or macrovascular complications, and to analyze the differences between the male and female patients with regard to the abovementioned parameters. Male patients with type II diabetes mellitus showed a positive correlation between NEFA concentrations and anti-oxLDL antibodies (r=0.334, p=0.019). A weak, but statistically significant correlation between adiponectin concentrations and the IgM isotype of anti-annexin A5 antibodies was found in type II diabetes mellitus patients (r=0.285, p=0.011). The presence of a positive correlation between NEFA and anti-oxLDL antibodies might be useful in the detection of patients with premature atherosclerosis in type II diabetes mellitus patients without any micro and/or macrovascular complications among type II diabetes mellitus patients.
Colwell JA. Treatment for the procoagulant state in type II diabetes. Endocrinol Metab Clin North Am 2001; 30: 1011-30.
Bećarević M, Andrejević S, Bonači-Nikolić B, Obradović I, Miljić P, Majkić-Singh N. Anti-oxLDL Antibodies - Marker for Arterial Thromboses in Antiphospholipid Syndrome? Clin Lab 2005; 51: 279-83.
Bećarević M, Singh S, Majkić-Singh N. Oxidized LDL, anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome. Clin Lab 2008; 54: 97-101.
Bećarević M, Andrejević S, Miljić P, Bonači-Nikolić B, Majkić-Singh N. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007; 25: 361-6.
Varaala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Intern Med 2000; 247: 381-4.
Rand JH, Wu XX, Quin AS, Chen PP, McCrae KR, Bovill EG, Taatjes DJ. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers. Am J Pathol 2003; 163: 1193-200.
Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006; 188: 231-44.
Popa C, Netea MG, Van Riel PLCM, Van der Meer JWM, Stalenhoef AFH. The role of TNH-alpha in chronic inflammatory conditions, intermediary metabolism and cardiovascular risk. J Lipid Res 2007; 48: 751-62.
McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
Lemieux I. Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Boil 2004; 24: 795-7.
Bećarević M, Seferović S, Ignjatović S, Singh S, Majkić-Singh N. Significant association of antiphospholipid antibodies and TNF-alpha: marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. Cytokine 2011; 55: 301-6.
American Heart Association: Heart and Stroke Facts. Dallas: American Heart Association, 1992.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
Xu A, Chan KW, Hoo RLC, et al. Testosterone selectively reduces the high molecular weight form of the adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-80.
Lanfranco F, Zitzman M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol 2004; 500-7.
Nischizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocy te-derived protein. Diabetes 2002; 51: 2734-41.
Urbonaviciene G, Frystyk J, Flyvbjerg A, Henneberg EW, Lindholt JS. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease. Atheriosclerosis 2010; 210: 619-24.
Masumi A, Otokozawa S, Asztalos BF, et al. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring study. Atherosclerosis 2011; 217: 543-48.
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose specific protein: adiponectin in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-19.
Higashiura K, Ura N, Ohata J, et al. Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol 2004; 61: 753-9.
Chan KC, Chou HH, Wu DJ, Wu YL, Huang CN. Diabetes mellitus has an additional effect on coronary artery disease - to decrease adiponectin level. Jpn Heart 2004; 45: 921-7.
Tshritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239-43.
Valsamakis G, Chetty R, Mcternan PG, et al. Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metabol 2003; 5: 131-5.
Gonzales-Sanches JL, Zabena CA, Martinez-Larrad MT, et al. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res 2005; 13: 807-12.
Choi KM, Lee KW, Seo JA, et al. The association between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol 2004; 150: 715-18.
Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor for predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: 103-4.
Nakamura Y, Shimada K, Fukada D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-33.
Randle PJ, Garland PB, Hales CN, Newsholm EA. The glucose fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; i: 785-9.
Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell function. Eur J Clin Invest 2002; 32: 14-23.
Carlsson M, Wessman Y, Almgren P, Groop L. High levels of non-esterified fatty acids are associated with increased familial risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 2000; 160: 1588-94.
Gillery P. Nonenzymatic post-translational modification derived products: New biomarkers of protein aging. Journal of Medical Biochemistry 2011; 30: 201-6.
Aslan D. Biomarkers for diabetes complications: The results of several clinical studies. Journal of Medical Biochemistry 2011; 30: 207-12.
Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 2008; 201: 17-32.
Iwashima Y, Horio T, Suzuki Y, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atheriosclerosis 2006; 188: 384-90.
Fortuno A, Rodriguez A, Gomez-Ambrosi J, Fruhbeck G, Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003, 59: 51-60.